9 results for "Lisa Sandmann"

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment

Lisa Sandmann; Birgit Bremer; Valerie Ohlendorf et al.

Viruses, Vol. 16 No. 2 · 2024 · English · DOAJ Scopus

Background: The hepatitis B core-related antigen (HBcrAg) correlates with HBV DNA in patients with chronic HBV infection without antiviral treatment. Its utility in monitoring patients during and after the cessation of nucleos(t)ide analog (NA) treatment is unknown. Methods: The levels of HBcrAg…

Limited stability of Hepatitis B virus RNA in plasma and serum

Valerie Ohlendorf; Birgit Bremer; Lisa Sandmann et al.

Scientific Reports, Vol. 14 No. 1 · 2024 · English · DOAJ Scopus

Abstract Pregenomic hepatitis B virus RNA (HBV pgRNA) is a potential biomarker in the management of HBV infected patients. However, prior to the use in routine clinical practice potential confounders of test results need to be identified. This study investigates the stability of HBV pgRNA under…

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

Markus Cornberg; Lisa Sandmann; Jerzy Jaroszewicz et al.

Journal of Hepatology · 2025 · English · OpenAlex Scopus

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

Lisa Sandmann; Cihan Yurdaydin; Katja Deterding et al.

Hepatology Communications, Vol. 6 No. 3 · 2022 · English · DOAJ Scopus

Standard treatment of hepatitis delta virus (HDV) infection remains pegylated‐interferon alfa (peg‐IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core‐related antigen (HBcrAg) is linked to intrahepatic covalently closed circular…

Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP)

Isabel Veloso Alves Pereira; Bettina Buchmann; Lisa Sandmann et al.

PLOS ONE, Vol. 10 No. 2 · 2015 · English · PLOS Scopus

Background: The sodium-taurocholate cotransporting polypeptide (NTCP) is both a key bile acid (BA) transporter mediating uptake of BA into hepatocytes and an essential receptor for hepatitis B virus (HBV) and hepatitis D virus (HDV). In this study we aimed to characterize to what extent and through…

Also available at: DOAJ

Hepatitis delta virus co-infection in patients with hepatocellular carcinoma and people living with HIV in Nigeria

Ijeoma Ifeorah; Birgit Bremer; Yusuf Musa et al.

BMC Infectious Diseases, Vol. 26 No. 1 · 2026 · English · DOAJ Scopus

Abstract Introduction Despite Nigeria’s high burden of hepatitis B virus (HBV), the epidemiological landscape of hepatitis D virus (HDV) remains largely unexplored. Consequently, HDV remains under-recognized as a public health concern, slowing down efforts to improve surveillance and clinical care…

Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D

Lisa Sandmann; Mathias Jachs; Tammo L. Tergast et al.

JHEP Reports, Vol. 8 No. 1 · 2026 · English · DOAJ Scopus

Background & Aims: Portal hypertension (PH) drives decompensation in patients with advanced chronic liver disease. Effects of antiviral treatment with bulevirtide (BLV) and achievement of suggested treatment endpoints on PH in patients with chronic hepatitis D (CHD) are unknown. Methods…

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022Key points

Pietro Lampertico; Elisabetta Degasperi; Lisa Sandmann et al.

JHEP Reports, Vol. 5 No. 9 · 2023 · English · DOAJ Scopus

Summary: Chronic infection with hepatitis delta virus (HDV) affects between 12-20 million people worldwide and represents the most severe form of viral hepatitis, leading to accelerated liver disease progression, cirrhosis and its complications, such as end-stage-liver disease and hepatocellular…